Supplementary Data from Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker <i>Post Hoc</i> Analysis of the VELOUR Trial

Figure legends and supplementary tables Supp Table 1. Patient demographics and baseline characteristics for the VELOUR ITT and biomarker populations. Supp Table 2. Mean plasma concentrations for the 98 biomarkers analyzed. Supp Table 3. Longitudinal analysis estimates of treatment effect by timepoint showing ANOVA p-value {less than or equal to} 0.0001 - Preprocessed data